Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Saturday, Roche Reports evERA Results: All-Oral Giredestrant And Everolimus Show Clinically Meaningful Progression-Free Survival Benefit

Author: Benzinga Newsdesk | October 20, 2025 01:40am

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with standard-of-care endocrine therapy plus everolimus1
The giredestrant combination was well tolerated; no new safety signals were observed including no photopsia1
Overall survival data were immature, but a clear positive trend was seen in both the ITT and ESR1-mutated populations1
If approved, giredestrant plus everolimus could be the first and only oral selective oestrogen receptor degrader combination in the post-CDK inhibitor setting

Posted In: RHHBF RHHBY RHHVF